Stacy Ku
Stock Analyst at TD Cowen
(2.40)
# 2,216
Out of 5,182 analysts
6
Total ratings
60%
Success rate
13.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRCE Grace Therapeutics | Maintains: Buy | $12 → $8 | $2.16 | +270.37% | 1 | Apr 24, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $45 → $60 | $49.33 | +21.63% | 1 | Oct 23, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reinstates: Buy | $30 | $8.90 | +237.08% | 1 | Oct 15, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | n/a | $39.51 | - | 1 | Jan 7, 2025 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $30 | $19.16 | +56.58% | 1 | Jan 7, 2025 | |
| VRCA Verrica Pharmaceuticals | Maintains: Buy | $150 → $100 | $6.83 | +1,365.20% | 1 | Oct 21, 2024 |
Grace Therapeutics
Apr 24, 2026
Maintains: Buy
Price Target: $12 → $8
Current: $2.16
Upside: +270.37%
Supernus Pharmaceuticals
Oct 23, 2025
Maintains: Buy
Price Target: $45 → $60
Current: $49.33
Upside: +21.63%
BioCryst Pharmaceuticals
Oct 15, 2025
Reinstates: Buy
Price Target: $30
Current: $8.90
Upside: +237.08%
Centessa Pharmaceuticals
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $39.51
Upside: -
KalVista Pharmaceuticals
Jan 7, 2025
Initiates: Buy
Price Target: $30
Current: $19.16
Upside: +56.58%
Verrica Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $150 → $100
Current: $6.83
Upside: +1,365.20%